Drugs / BEBT-507
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07012109 | Jun 2025 → Jan 2028 expected | acquired polycythemia vera | BeBetter Med Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEBT-507 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07012109 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07012109 ↗ |